GlassScriptPhysician profile
Amy D Mcdowell
NPI 1568051324
$21,508.88
in general payments reported to CMS, 2019-2025
33 companies · $10K in 2025
The $10K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,069 · 2022: $2,618 · 2023: $3,295 · 2024: $4,358 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $3,816 · Travel and Lodging: $997 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,901.76 |
| Consulting Fee | $3,816.00 |
| Travel and Lodging | $996.81 |
| Education | $106.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,132.93 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $2,624.85 | 2022-2025 | Ilumya, Blu-U, Odomzo |
| Janssen Scientific Affairs, LLC | $1,795.34 | 2021-2025 | Tremfya |
| Abbvie INC. | $1,692.55 | 2021-2025 | |
| Janssen Biotech, INC. | $1,400.02 | 2022-2025 | Tremfya |
| Galderma Laboratories, L.P. | $1,286.63 | 2023-2025 | Nemluvio, Aklief, Dysport |
| Botanix Sb INC | $1,162.84 | 2025 | Sofdra |
| Genzyme Corporation | $1,073.36 | 2022-2025 | |
| Epi Health, LLC | $1,024.86 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $1,023.80 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $751.94 | 2023-2025 | Zoryve |
| Pfizer INC. | $661.76 | 2022-2025 | |
| Amgen INC. | $651.48 | 2023-2025 | Otezla, Otezla |
| Lilly USA, LLC | $649.58 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $587.92 | 2021-2025 | Dupixent, Libtayo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $524.87 | 2023-2024 | Vtama |
| Incyte Corporation | $333.06 | 2022-2025 | Opzelura |
| Organon LLC | $256.41 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $152.60 | 2022-2024 | |
| Verrica Pharmaceuticals INC. | $106.28 | 2023-2025 | Ycanth |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Journey Medical Corporation | $80.05 | 2022-2025 | |
| Organogenesis INC. | $64.90 | 2025 | Novachor, Via Matrix |
| Ucb, INC. | $62.44 | 2024-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.78 | 2023 | Spevigo |
| Cipher Pharmaceuticals US LLC | $50.33 | 2025 | Spinosad, Natroba |
| Biofrontera INC. | $39.65 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Smith+Nephew, INC. | $37.44 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.55 | 2021-2024 | Cabtreo |
| Lnhc, INC | $29.94 | 2025 | Zelsuvmi |
| Leo Pharma INC. | $23.33 | 2024 | Adbry |
| Phadia US INC. | $20.55 | 2022 | |
| Bioventus LLC | $17.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Mcdowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.